In a follow-up crossover study to evaluate the hormone’s potential neuroprotective effects, Kristensen et al. either administered exogenous EPO or placebo to 11 T1DM patients with IAH and recurrent severe hypoglycemia six days before a hypoglycemic clamp procedure design [28]. Here, EPO is linked to type 1 diabetes mellitus.